Testing nirogacestat for Kaposi sarcoma
Treatments studied
Part of Cancer, Immune system & allergy, Infections, Skin clinical trials.
This trial tests a new drug called nirogacestat to see if it can shrink Kaposi sarcoma lesions. It is for people with Kaposi sarcoma that has not improved with standard treatment or who cannot tolerate standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Kaposi sarcoma that has been confirmed with a biopsy (a small sample of the lesion is taken and examined under a microscope).
- The cancer may be new or have not improved despite previous treatment (or you couldn't tolerate the treatment).
- You have at least one skin lesion that is at least 4 millimeters (about the size of a peppercorn) and are willing to have it biopsied multiple times.
- If you are HIV-positive, you must be on stable HIV medication (antiretroviral therapy) for at least 12 weeks, with a CD4 count above 50 and a viral load below 200 copies/mL.
- Your organs (kidneys, liver, blood counts) need to be functioning adequately, as checked by blood tests.
- You are not taking certain medications (including some HIV drugs, antifungals, St. John's Wort, or others) that could interfere with the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two chemotherapy drugs, paclitaxel and pegylated liposomal doxorubicin, to see which works better for HIV-related Kaposi sarcoma. It aims to find a more effective treatment to shrink skin lesions and improve quality of life.
This trial tests if the blood pressure medication propranolol can treat Kaposi Sarcoma (a type of skin cancer) in adults. You may be able to join if you have at least 7 measurable skin lesions and are otherwise healthy enough to take an oral pill.
This trial tests a special imaging device to see if it can better evaluate Kaposi sarcoma skin lesions. It may help doctors understand the extent of the disease without relying only on physical exams.
This trial tests an experimental drug (CYT107) that boosts the immune system to help fight Kaposi sarcoma in people with HIV who have a low CD4 count despite good HIV treatment. It aims to see if the drug can improve KS tumors and quality of life.
This trial studies ixazomib (a targeted anti-cancer medicine) to treat cutaneous (skin) Kaposi sarcoma. It aims to shrink measurable skin lesions and improve symptoms, especially in people living with HIV.
This Phase 1/2 study tests PDS01ADC, a targeted cancer drug, for advanced Kaposi sarcoma (KS). It also studies how well the drug works when added to the immunotherapy M7824, especially if KS has not responded to prior treatments.
Hear when a new AIDS-Related Kaposi Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.